Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 13/20 | 0.58 |
| ▸ | FAP | Q12884 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 1/20 | 0.49 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13958643 | 0.92 | P2RX7 (0.58) | P2RX7ALDH1A1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4505010 | 0.85 | NSD2 (0.53) | P2RX7SMN1; SMN2 | |
| SCHEMBL4492459 | 0.81 | P2RX7 (0.63) | P2RX7PREP | |
| SCHEMBL4511152 | 0.80 | P2RX7 (0.61) | P2RX7ALDH1A1 | |
| SCHEMBL4519721 | 0.79 | TACR3 (0.62) | P2RX7ALDH1A1SMN1; SMN2 | |
| SCHEMBL13972671 | 0.78 | NSD2 (0.53) | P2RX7SMN1; SMN2PREP | |
| SCHEMBL12586606 | 0.78 | P2RX7 (0.56) | P2RX7ALDH1A1 | |
| SCHEMBL4506684 | 0.78 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL5710569 | 0.78 | P2RX7 (0.65) | P2RX7ALDH1A1 | |
| SCHEMBL3641257 | 0.75 | HTR3A (0.52) | P2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090524-A1 | Novel adamantane derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 732/4885FAP 3630/4885ALDH1A1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.